Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma

Jingpiao Bao1,2†, Chaoliang Xu3†, Bin Li1,2, Zengkai Wu1,2, Jie Shen1,2, Pengli Song1,2, Qi Peng1,2 and Guoyong Hu1,2*

1 Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2 Shanghai Key Laboratory of Pancreatic Disease, Institute of Pancreatic Disease, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 3 Laboratory of Cancer Genomics and Biology, Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with poor prognosis. Karyopherin subunit alpha 4 (KPNA4) is a nuclear transport factor and plays tumor-promoting roles in multiple cancers. However, the roles of KPNA4 in PDAC still remain unknown. This study investigated the prognostic value of KPNA4 and its potential functions in PDAC and tumor microenvironment.

Methods: LinkedOmics was utilized to screen genes with survival significance in PDAC. KPNA4 expression was analyzed using multiple datasets and verified in PDAC cells and clinical samples by qRT-PCR and immunohistochemistry. Clinical correlation and survival analyses were conducted to identify the clinical significance and prognostic value of KPNA4 in PDAC patients. Subsequently, KPNA4 was knocked down in PDAC cell lines, and CCK-8, colony formation and wound healing assays were performed to test the functions of KPNA4 in vitro. Immune infiltration analysis was performed to explore the potential roles of KPNA4 in the tumor microenvironment of PDAC. Moreover, functional analyses were conducted to explore the underlying mechanism of KPNA4 in the progression of PDAC.

Results: We found KPNA4 was significantly upregulated in PDAC cells and tissues. KPNA4 expression was associated with tumor progression in PDAC patients. Survival analyses further revealed that KPNA4 could act as an independent predictor of unfavorable survival for PDAC patients. KPNA4 knockdown suppressed the viability, colony formation and migration of PDAC cells. Moreover, KPNA4 was correlated with immunosuppressive cells infiltration and T cell exhaustion in the tumor microenvironment of PDAC. Finally, functional analyses indicated the association of KPNA4 with focal adhesion kinase (FAK) signaling, and KPNA4 silencing significantly decreased the expression of FAK and PD-L1.

Conclusions: This study revealed that KPNA4 is an independent prognostic biomarker for PDAC and plays a tumor-promoting role by facilitating proliferation and migration of cancer cells and participating in immune infiltration, which may be mediated by FAK.
INTRODUCTION

In the United States, pancreatic cancer is predicted to be the second most common cause of cancer death by 2030, with the lowest 5-year survival rate among common solid cancers (1, 2). Also in China, the 5-year survival rate of pancreatic cancer is only 9.9%, which has not improved obviously over the past decade, and is expected to continue to rise (3). Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, and more than half of patients are diagnosed at an advanced stage and have systemic metastases, with only 15-20% of patients having the chance of surgical resection (2, 4). At present, the management of PDAC in China is still mainly based on surgery, chemotherapy and radiotherapy, supplemented by interventional therapy, best supportive care and traditional Chinese medicine (5). Despite the considerable improvements in surgical therapy, PDAC still carries a dismal prognosis (4). Also, conventional cytotoxic chemotherapy has an extremely limited effect on the prognosis (6). Therefore, it is necessary to further explore the occurrence and development mechanisms of PDAC and discover highly effective prognostic biomarkers, so as to improve the disease prediction and therapy decision of PDAC.

Desmoplasia is a key histopathological feature of PDAC, manifested by extensive fibrosis surrounding primary and metastatic tumor sites (7). The highly fibrotic stroma can act as a mechanical barrier for tumor cells, thus creating a tumor microenvironment (TME) conducive to tumor growth, where therapeutic drugs are difficult to reach and immune cells exhibit a poor infiltration (8). In addition, PDAC is recognized as an immunologically cold tumor type (9). These may explain why PDAC patients are likely responsive to immune checkpoint inhibitors (10). Therefore, further research on PDAC TME is urgently needed to find ways to maximize the tumoricidal activity of immune cells, thus enhancing the anti-tumor response.

Karyopherin subunit alpha 4 (KPNA4), which is a member of the nuclear transport factors KPNA family, has been reported to be associated with multiple cancers, including prostate cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, glioblastoma and other malignancies. These studies reveal that KPNA4 exerts a tumor-promoting role by facilitating cell cycle progression, epithelial-mesenchymal transition (EMT), angiogenesis and other cancer-related processes (11–16). Moreover, KPNA4 was found to be correlated with immune cell infiltration in hepatocellular carcinoma (16), suggesting that KPNA4 expression may have an effect on TME and anti-tumor immunity. However, so far, the potential function of KPNA4 in PDAC and its impact on the TME still remain to be elucidated.

In this study, we aimed to analyze the expression and prognostic value of KPNA4 in PDAC and identified KPNA4 as a potential prognostic biomarker for PDAC through bioinformatics analysis. Loss-of-function experiments revealed that KPNA4 exerts a promoting role in malignant behaviors of PDAC cells. Moreover, immune infiltration analysis further revealed the potential immunosuppressive effect of KPNA4 on PDAC TME. Finally, functional analyses demonstrated that KPNA4 may be involved in focal adhesion kinase (FAK) signaling, which can promote tumor progression and metastases by acting on tumor cells and stromal cells in the tumor microenvironment (17). Our experimental data revealed the positive regulatory effect of KPNA4 on the expression of FAK and immune checkpoint molecule PD-L1. Our results are expected to provide new ideas for the prognosis prediction and targeted therapy of PDAC.

MATERIALS AND METHODS

Identification of Genes With Survival Significance in PDAC

LinkedOmics (http://www.linkedomics.org/) is a publicly accessible online database to analyze multi-omics data from 32 kinds of TCGA human cancer (18). This database has the unique ability to display the survival significance of all human genes in specific tumor types. Thus, in our study, in order to find immune-related biomarkers with potentially high prognostic value in PDAC, LinkedOmics was utilized to obtain a list of genes with survival significance in PDAC, and these genes were ranked by their false discovery rate (FDR) value.

Analyses of KPNA4 Expression and Its Correlation With FAK Signaling-Related Genes

Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn/) is a multifunctional online database for analyzing gene expression and clinical data from TCGA and the GTEx database, containing 9,736 tumors and 8,587 normal samples (19). Considering the scarcity of RNA-seq data of normal pancreas sample (e.g. only four normal samples in TCGA), GEPIA can largely compensate for this problem. GEO (http://www.ncbi.nlm.nih.gov/geo/) is a public database that collects microarray, high-throughput sequencing and other forms of data uploaded by global researchers, providing a large number of datasets for verifying the expression changes of target genes (20, 21). In the present study, GEPIA and two PDAC microarrays GSE15471 and GSE16515 obtained from the GEO database were utilized to analyze the mRNA expression of KPNA4 in PDAC and normal samples, as well as its correlation with FAK signaling-related genes (FAK, PIK3CA, AKT1 and CD274). To further enrich the dataset sources,
Oncomine (http://www.oncomine.org/), which contains various tumor microarray datasets, was also used to verify the expression change of KPNA4 in microarrays of PDAC tissues. The Human Protein Atlas (HPA) (http://www.proteinatlas.org/) is a publicly available database for human proteins mapping in cells, tissues and organs by various omics technologies, providing the expression of the target gene at the protein level (22). In this study, HPA was utilized to obtain the immunohistochemical expression of the target gene at the protein level (22). In this study, HPA was utilized to obtain the immunohistochemical images of KPNA4 expression in normal pancreas and PDAC tissues, then direct comparison was performed between the two groups. $p < 0.05$ was regarded to be statistically significant.

**Clinical Samples and Immunohistochemical Staining**

PDAC and adjacent normal pancreas samples were surgically obtained from twenty-three patients to validate the upregulation of KPNA4 in PDAC. This work was approved by the Ethics Committee of Shanghai General Hospital (approval number: 2021KY116). The clinical characteristics of each patient are shown in Supplementary Table 1. Immunohistochemical staining of the paraffin-embedded tissue sections were conducted following standard protocols. The tissue sections were incubated overnight with a rabbit polyclonal antibody to human KPNA4 (Sigma-Aldrich, HPA043154). The histochemistry score was determined by multiplying the stained intensity scores by the extent of positive cells. The stain intensity was scored as follows: 0, blank; 1, yellow; 2, dark yellow; and 3, brown. The extent of positive cells was scored as follows: 0, 0-5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. All slides were independently accessed by two experienced pathologists in a blinded fashion.

**Clinical Relevance Analysis of KPNA4 in PDAC**

The Cancer Genome Atlas (TCGA) (http://portal.gdc.cancer.gov/) is a landmark cancer genomics project, providing sequencing and clinical information for 33 types of human cancer (23). mRNA expression data of 177 PDAC and 4 normal pancreas samples determined by the value of Fragments Per Kilobase per Million, and incomplete clinical data of 185 PDAC patients were obtained from TCGA database. In our study, 173 PDAC samples with mRNA expression and clinical data were used to perform clinical correlation and stratified survival analysis of KPNA4. Furthermore, 120 PDAC samples with KPNA4 expression and complete clinical information were included in Cox regression analysis. OSPaad (http://bioinfo.henu.edu.cn/PAAD/PAADList.jsp/), which contains transcriptional expression and survival data of a total of 1319 PDAC cases from TCGA, ICGC and the GEO databases (GSE28735, GSE62452 and GSE71729) (24), was used to further validate the survival significance of KPNA4 in PDAC patients. $p$ value < 0.05 was considered as statistically significant.

**Cell Culture and Treatment**

The human normal pancreatic ductal epithelial cell line HPDE6-C7 and PDAC cell lines (SW1990, MIA PaCa-2, BxPC-3 and PANC-1) were all obtained from Type Culture Collection of the Chinese Academy of Science (Shanghai, China). SW1990 was cultured in RPMI 1640 medium (Gibco), and HPDE6-C7, BxPC-3, MIA PaCa-2 and PANC-1 were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco). The medium was supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin (Gibco). All the cells were incubated in a humidified atmosphere containing 5% CO2 at 37°C. The cell culture media was replaced every 2-3 days.

To determine the function of KPNA4 in PDAC cell lines, siRNA that targeted human KPNA4 (siKPNA4) and its negative control (siNC) were synthesized by Ribobio (Guangzhou, China). Three different KPNA4-specific siRNA were designed for this study (siKPNA4-1: GCCGAACAUUGGUUCAATT, siKPNA4-2: GCAGUAUUGUGCCAAUCTT, siKPNA4-3: CCACCACCAAUGGAA ACCATT), and siKPNA4-3 was selected for further loss-of-function experiments because of its high inhibition efficiency. Transient transfection in these PDAC cells was carried out by using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instructions. In our preliminary experiments, MIA PaCa-2 and PANC-1 in the 6-well-plates were treated with siKPNA4 at different concentrations (10, 50 and 100 nM) and Lipofectamine 3000 at different volumes (2, 4, 6 and 8 µL), and results showed that 100nM siKPNA4 concentration and 4 µL Lipofectamine were the most effective and safe conditions for KPNA4 knockdown.

**Cell Viability and Colony Formation Assays**

Cell Counting Kit-8 (CCK-8) assay and colony formation assay were performed in our study to evaluate the proliferation ability of PDAC cell lines. Briefly, for CCK-8 assay, MIA PaCa-2 and PANC-1 cells after transient transfection for 48 hours were seeded into the 96-well-plates (1000 per well), and cultured for 0, 24, 48, 72 and 96 hours. Cell viability was then examined by using the CCK-8 reagent (Dojindo, Kumamoto, Japan), and the absorbance at 450 nm was determined by the microplate reader after 2 hours incubation, with six wells per group being analyzed. For colony formation assay, cells were seeded into the 6-well-plates (1000 per well) and cultured for 7-10 days until visible colonies formed. Then, the colonies were stained with crystal violet and quantified by using Image J software, with three wells per group being analyzed.

**Wound Healing Assay**

Wound healing assay was carried out in this study to investigate the migration ability of PDAC cell lines. MIA PaCa-2 and PANC-1 cells after transient transfection for 48 hours were seeded into the 6-well-plates. After cells had reached confluence, a scratch was made by a 200 µL pipette tip. Cell debris was washed away with PBS, and the medium was replaced with fresh serum-free DMEM. The wound area was photographed by using a microscope every 24 hours, with three wells per group being analyzed.

**Correlation Between KPNA4 and Tumor-Infiltrating Immune Cells**

Tumor Immune Estimation Resource (TIMER) (https://cistrome.shinyapps.io/timer/) and TIMER2.0 (http://timer.cistrome.org/) are powerful tools that can evaluate the potential impact of genes of interest on immune cell...
infiltration in the TME of different cancer types (25). In our work, TIMER and TIMER2.0 database were used to analyze the correlation between KPNA4 expression and various immune cells infiltration in PDAC. \(p\) value < 0.05 was regarded to be statistically significant.

**Functional Enrichment Analyses and Protein–Protein Interactions (PPI) Network**
LinkedOmics was used to obtain the list of KPNA4 co-expressed genes in PDAC. The 200 positively and 200 negatively related genes with the highest correlation coefficients were included in the subsequent functional enrichment analyses.

Gene Ontology (GO) analysis composed of biological process (BP), molecular function (MF) and cellular component (CC), along with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis are well-known methods to predict biological functions of gene and gene clusters. To investigate the potential roles of KPNA4 in PDAC, GO and KEGG pathway analysis were carried out on KPNA4 co-expressed genes through The Database for Annotation, Visualization, and Integrated Discovery (DAVID) (http://david.ncifcrf.gov/) (26, 27). \(p\) value < 0.05 were accepted as statistically significant. In addition, the “clusterProfiler” R package was used to perform Gene Set Enrichment Analysis (GSEA) and the “enrichplot” R package was utilized to visualize the result. A nominal \(p\) value < 0.05 and FDR < 0.25 were considered to be a significantly enriched gene set.

**Quantitative Real-Time PCR (qRT-PCR) Analysis**
Total RNA of cell lines was extracted with Trizol reagent (Takara) and reverse-transcribed into cDNA using PrimeScript RT Master Mix (Takara) according to the manufacturer’s instructions. To determine the expressions of KPNA4 and FAK signaling-related genes in PDAC cell lines at the mRNA level, qRT-PCR analysis was performed with SYBR Premix Ex Taq II (Takara) in the QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems) with GAPDH as an internal control. Each sample was run in triplicate, and the experiments were repeated three times independently. All qRT-PCR reactions were conducted with the following settings: 95°C for 30 s; 40 cycles of 95°C for 5 s and 60°C for 34 s. The comparative CT method (\(2^{-\Delta\Delta CT}\)) was applied to calculate the relative expression of KPNA4. The specific sequences of primers used are as follows: KPNA4 (forward CTGGACCAAAACCTGGAGCAt; reverse AAGTGCTGGCAAGTTAACG), FAK (forward CTTCGGACACGGGTAGATAAGCC), FAK (forward CTTCCGGACACGGGTAGATAAGCC), reverse AGTTGCACAGGTCCAT (TGAT), PIK3CA (forward GGTTGGGCTGTGTTGAG; reverse CACCGTGGCCACCTGGCATA), AKT1 (forward CAGGATGTGCGCAACAGTGA; reverse AAGTGCTGGCAAGTTAACG), CD274 (forward GTTGATGGATGATCCAGTCACCTCT; reverse GGTCACCTGTTGTCGAGATGA), GAPDH (forward AACGGATTTGGCAGATTG; reverse GGAAGATGGGTGATGGGATT).

**Statistical Analysis**
SPSS software version 20.0 was utilized for statistical analysis in our study. Wilcoxon matched-pairs signed rank test was performed to determine the expression differences of KPNA4 between paired PDAC and normal pancreas samples in GSE15471, while Welch’s \(t\) test was performed in unpaired samples of GSE16515. The potential correlation between KPNA4 expression and clinicopathologic characteristics in TCGA PDAC cohort was analyzed by Mann-Whitney test because the expression value disobeyed the Gaussian distribution. The association between KPNA4 histocherey score and clinicopathologic parameters of our own PDAC clinical samples was analyzed by Pearson Chi-squared test. Cox regression analysis was carried out to evaluate the predictive value of KPNA4 in PDAC prognosis, and KPNA4 expression was input as a categorical variable according to the median expression value. The factors with \(p\)-value < 0.2 in the univariate analysis were included in the subsequent multivariate analysis, where \(p\)-value < 0.05 was regarded to be statistically significant. Moreover, survival curves were generated by Graphpad Prism 7, and Log-rank test was implemented to determine the significant differences. Finally, correlation between KPNA4 and FAK signaling-related genes in GSE15471 and GSE16515 was analyzed by the “stats” R package, and the “ggstatsplot” R package was used to visualize the result. The experimental data were presented as the mean ± standard deviation and each experiment was repeated three times per condition.

**RESULTS**
**KPNA4 Is Overexpressed in PDAC Samples**
To excavate a novel immune-related biomarker with high prognostic value for PDAC patients, we first utilized the LinkedOmics database to obtain a list of genes with survival significance in TCGA PDAC, and ranked these genes according to their FDR value (Figure 1A and Supplementary Table 2). Remarkably, among the top six genes, KPNA4 was the only one which has been reported to be associated with immune infiltration in malignancy while its roles in PDAC have not been studied yet (16). In addition, analysis via GEPIA database indicated that KPNA4 was significantly upregulated in PDAC tissues (Figure 1B). Furthermore, KPNA4 expression was significantly elevated in many other tumors including diffuse large B cell lymphoma (DLBC), esophageal carcinoma (ESCA), lung squamous cell carcinoma (LUSC) and stomach adenocarcinoma (STAD) (Supplementary Figure 1A). Therefore, we focused on KPNA4 for further analysis.

Next, we used Oncomine database to verify the expression of KPNA4 in PDAC. As shown in Supplementary Figure 1B, although KPNA4 showed discordant expression change in most cancer types, it was consistently upregulated in five
cohort of PDAC. Another cohort showed that KPNA4 was also increased in pancreatic intraepithelial neoplasia, which is a precancerous lesion of pancreatic cancer (Table 1). In addition, two datasets from the GEO database (GSE15471 and GSE16515) consistently showed that the level of KPNA4 was significantly upregulated in PDAC tissues (Figure 1C). To further verify the KPNA4 expression at the protein level, we compared the immunohistochemical staining of KPNA4 in normal pancreas and PDAC through the HPA database. The result again showed that KPNA4 expression in PDAC was markedly higher than that of normal pancreas, and KPNA4 showed obvious nuclear localization (Figure 1D).

To finally confirm, we measured the mRNA levels of KPNA4 in cell lines by qRT-PCR, and then the protein levels in PDAC tissues by immunohistochemistry. qRT-PCR analysis revealed that KPNA4 expression was remarkably elevated in PDAC cell lines SW1990, BxPC-3, MIA PaCa-2, and PANC-1 compared with that of human normal pancreatic ductal epithelial cell line HPDE6-C7 (Figure 1E). Immunohistochemistry further verified the upregulation of KPNA4 in our own clinical samples (Figure 1F). Altogether, these results suggest that KPNA4 may be a potential biomarker for PDAC.

**KPNA4 Is Closely Correlated With Clinicopathologic Characteristics of PDAC**

To investigate the relationship between KPNA4 expression and clinicopathologic characteristics of PDAC patients, we initially analyzed the expression pattern of KPNA4 in patients with different TNM stages and histological grades. Although the expression level of KPNA4 was particular low in both Stage-3 and Grade-4 samples, probably due to the small sample sizes (only three Stage-3 samples and two Grade-4 samples), patients with higher stage and histological grade tended to express higher level of KPNA4 (Figures 2A, B).
To further analyze the correlation of KPNA4 with other clinicopathologic parameters, 173 PDAC samples with expression profiles and clinical data were downloaded from TCGA database, and then clinical correlation analysis were performed. The result showed that KPNA4 expression had no correlation with age, gender, M stage, diabetes mellitus (DM) history, chronic pancreatitis (CP) history and tumor size (Figures 2C, D, G–K). However, tumors with higher T stage or N stage had a tendency to express higher level of KPNA4 (Figures 2E, F), indicating that KPNA4 may promote tumor infiltration and lymph node metastasis. Notably, patients with higher KPNA4 expression showed significantly poorer responses to primary therapy and radiotherapy (Figures 2L, M), suggesting that high KPNA4-expressed patients may be less sensitive to conventional therapies for PDAC. Additionally, the association between KPNA4 expression and clinicopathologic parameters of our own clinical samples is shown in Supplementary Table 3. The result showed that the high-KPNA4 group had a significantly higher ratio of patients in advanced TNM stage and histological grade, compared to the low-KPNA4 group. Altogether, these results suggest that KPNA4 expression is associated with tumor progression in PDAC patients.

### Table 1: KPNA4 expression change between PDAC and normal pancreas tissues (Oncomine).

| Disease Type VS. Normal pancreas | Fold Change | p-Value | Reference |
|----------------------------------|-------------|---------|-----------|
| Pancreatic Ductal Adenocarcinoma | 1.527       | 1.87E-06| (30)      |
| Pancreatic Adenocarcinoma        | 1.349       | 1.79E-04| (31)      |
| Pancreatic Carcinoma             | 1.761       | 7.89E-04| (32)      |
| Pancreatic Intraepithelial Neoplasia | 1.190     | 1.80E-02| (33)      |
| Pancreatic Ductal Adenocarcinoma | 1.504       | 3.40E-02| (34)      |
| Pancreatic Carcinoma             | 1.297       | 3.90E-02| (35)      |

p-Value less than 0.05 are in italics.
High-Expressed KPNA4 Is Independently Associated With a Poor Clinical Outcome in PDAC Patients

Next, we evaluated the survival significance of KPNA4 in PDAC patients. As we expected, patients with higher KPNA4 expression showed significantly worse overall survival and disease-free survival (Figures 3A, B). Additionally, we verified the survival significance of KPNA4 in a larger cohort via OSpaad, which is a web tool containing survival information of a total of 1319 PDAC cases from multiple databases. The result again showed that high KPNA4 expression was associated with unfavorable survival outcome (Figure 3C). Subsequently, we carried out stratified survival analysis on 173 PDAC samples from TCGA database. The results further revealed that high KPNA4 expression had a significant correlation with poor survival in patients regardless of histological grades (Figures 3D, E), indicating that the prognostic value of KPNA4 was independent of tumor malignancy. Similar results were observed when patients were stratified by T stage (Figures 3F, G). In addition, high KPNA4 expression also indicated poor survival outcome when patients were stratified by N stage, although the result was not statistically significant (Figures 3H, I).

To further assess the prognostic value of KPNA4 in PDAC, we performed Cox regression analysis on 120 PDAC samples with complete clinical information and transcriptome data from TCGA database. Univariate analysis indicated that higher T stage, N stage and histological grade, larger tumor size and higher KPNA4 expression were all correlated with worse survival (Table 2). While in multivariate analysis, only KPNA4 expression was significantly correlated with the prognosis of PDAC patients. Taken together, KPNA4 holds great prognostic value among PDAC patients and thus could be a promising candidate of prognostic biomarker of PDAC.

Knockdown of KPNA4 Inhibits PDAC Cell Proliferation and Migration

To demonstrate the role of KPNA4 in the malignant behaviors of tumor cells, we first evaluated the transfection efficiency of
siKPNA4 by qRT-PCR. We used siKPNA4-3 for further studies because it had the most obvious inhibitory effect on KPNA4 in Mia PaCa-2 and PANC-1 cells (Figure 4A). We performed CCK-8 assay to determine the effect of KPNA4 knockdown on cell proliferation. The results indicated that KPNA4 silencing significantly repressed Mia PaCa-2 and PANC-1 cell proliferation (Figures 4B, C). Colony formation assay also showed that KPNA4 knockdown significantly inhibited the growth of these two PDAC cells (Figures 4D, E). Wound healing assay further revealed that after KPNA4 knockdown, the migration ability of Mia PaCa-2 and PANC-1 cells decreased significantly compared with control cells (Figures 4F–I). In conclusion, these experimental data confirmed knockdown of KPNA4 suppresses cell proliferation and migration in PDAC cells.

**KPNA4 Is Correlated With The Infiltration of Immunosuppressive Cells and T Cell Exhaustion in PDAC TME**

Given that immune cells in the TME have a central role in tumorigenesis and progression of PDAC (6), we next utilized TIMER database to analyze the association between KPNA4 expression and immune infiltration in PDAC. As shown in Figure 5A, KPNA4 expression had a significant positive correlation with the infiltration of CD8+ T cells, macrophages, neutrophils and dendritic cells (DCs). TIMER2.0 database further revealed that the expression of KPNA4 was also positively correlated with the infiltration of regulatory T cells (Tregs) and cancer-associated fibroblasts (CAFs) (Figure 5B). While macrophages, neutrophils, DCs, Tregs and CAFs has been reported to have pro-tumorigenic effects in the TME (6, 36–39), the KPNA4-correlated infiltration of CD8+ T cells seemed to be inconsistent with the potential tumor-promoting role of KPNA4. Therefore, we further analyzed the relationship between the expression of KPNA4 and cytotoxic CD8+ T cells markers GZMA, GZMB and IFNG in PDAC. Intriguingly, KPNA4 showed no significant relationship with these effector genes (Figures 5C–E). Moreover, we explored the association between the expression of KPNA4 and exhausted T cells markers. Although no significant correlation was found between expression levels of KPNA4 and those of PDCD1 (PD-1), CTLA4, LAG3 or TIGIT (Figures 5F, G and Supplementary Figures 2A, B), we did find KPNA4 was closely associated with HAVCR2 (Figure 5H), which encodes the immune checkpoint receptor TIM3 and is tightly associated with poor prognosis of pancreatic cancer (40). In summary, these results suggest that high-expressed KPNA4 in PDAC may correlate with immunosuppressive cells infiltration and T cell exhaustion, thereby inhibiting anti-tumor immunity.

**Functional Analyses Associate KPNA4 With Focal Adhesion in PDAC**

To further explore the potential function and the underlying mechanism of KPNA4 in PDAC, we obtained KPNA4 co-expressed genes in TCGA PDAC via LinkedOmics database (Supplementary Table 4). Next, the 200 positively and 200 negatively correlated genes with the highest correlation coefficient were selected as the KPNA4 co-expressed gene set, and then functional enrichment analysis were carried out (Supplementary Figures 3A, B). The GO and KEGG pathway analysis revealed that KPNA4 was mainly involved in the regulation of cell-cell adhesion, cell-matrix adhesion and actin cytoskeleton remodeling (Figures 6A–D). Moreover, KEGG analysis showed that KPNA4 may also participate in regulating PI3K-Akt signaling pathway, which is a well-described therapeutic target for PDAC (Figure 6D) (41). Interestingly, focal adhesion is a type of integrin-mediated adhesive contact between cells and extracellular matrix, and its intracellular structure is tightly connected with the actin cytoskeleton, thereby regulating cell adhesion, cell motility and multiple cancer-related pathways including PI3K-Akt signaling (42, 43). Therefore, these results suggested that KPNA4 may regulate focal adhesion in PDAC. Furthermore, we analyzed KPNA4 co-expressed genes by constructing a PPI network, and used Cytoscape software to identify the hub genes (Figure 6E). Noticeably, these hub genes were all positively correlated with KPNA4, and KEGG pathway analysis demonstrated that these genes were mostly enriched in PI3K-Akt signaling and focal adhesion (Supplementary Figure 3C), which further confirmed our previous assumption. Moreover, GSEA was performed for further investigation. Consistent with our finding of KPNA4 in vitro, the results revealed that genes involved in the G2/M checkpoint, genes

**TABLE 2 | Univariate and multivariate Cox regression analyses of prognostic factors for overall survival in PDAC patients.**

| Risk factors | Univariate analysis | Multivariate analysis |
|-------------|---------------------|----------------------|
|             | HR                  | 95% CI                | p-Value | HR                | 95% CI | p-Value |
| Age (<60 vs. ≥60) | 1.144 | 0.604-2.166 | 0.679 | 2.192 | 0.757-6.344 | 0.148 |
| Gender (Female vs. Male) | 0.800 | 0.458-1.400 | 0.435 | 1.328 | 0.800-2.192 | 0.268 |
| T stage (T3+4 vs. T1+2) | 1.491 | 0.202-11.005 | 0.695 | 1.328 | 0.800-2.192 | 0.268 |
| N stage (N1 vs. N0) | 3.389 | 1.328-8.650 | 0.011 | 1.333 | 0.732-2.430 | 0.347 |
| Histological grade (G3+4 vs. G1+2) | 2.512 | 1.277-4.939 | 0.008 | 1.282 | 0.558-2.946 | 0.558 |
| DM history (YES vs. NO) | 1.545 | 0.877-2.721 | 0.132 | 1.333 | 0.732-2.430 | 0.347 |
| CP history (YES vs. NO) | 2.192 | 0.757-6.344 | 0.148 | 1.282 | 0.558-2.946 | 0.558 |
| Alcohol history (YES vs. NO) | 1.328 | 0.800-2.192 | 0.268 | 1.333 | 0.732-2.430 | 0.347 |
| Tumor size (≥3.5cm vs. <3.5cm) | 1.328 | 0.800-2.192 | 0.268 | 1.333 | 0.732-2.430 | 0.347 |
| KPNA4 expression | 1.375 | 0.753-2.509 | 0.300 | 1.889 | 1.020-3.497 | 0.043 |

*p-Value less than 0.2 in univariate analysis and 0.05 in multivariate analysis are in italics.
encoding cell cycle related targets of E2F transcription factors, and genes related to EMT were notably enriched in high KPNA4-expressed samples (Figure 6F and Supplementary Table 5), suggesting that KPNA4 was also involved in these cancer-related pathways.

**KPNA4 Is Positively Related to FAK Signaling and PD-L1 Expression**

FAK overexpression has been considered as one of the key features of PDAC (44). Moreover, several studies have shown that PI3K pathway, which has been reported to promote tumor progression and metastasis, and restrict T cell recognition and clearance of tumor cells in pancreatic cancer (45, 46), is one of the main downstream signals of FAK (47). FAK-PI3K-Akt signaling is also important in non-neoplastic diseases, for example, this signaling pathway plays a key role in hepatic stellate cell proliferation and type I collagen expression in liver fibrosis (48). Given that KPNA4 may affect focal adhesion and PI3K-Akt signaling in our functional analysis, we next investigated the expression correlation of KPNA4 with FAK, PI3K...
PIK3CA and AKT1 in TCGA PDAC. Remarkably, KPNA4 was found to be positively related to FAK, PIK3CA and AKT1 with high correlation coefficient (Figure 7A). We further verified these correlations in two PDAC microarrays from the GEO database. The results showed that KPNA4 was highly positively correlated with FAK and PIK3CA in GSE15471 (Figures 7B, C), although there was no significant correlation with AKT1 (Figure 7D). Also, the expression of KPNA4 showed a positive correlation with all these genes in GSE16515 (Supplementary Figures 4A–C). These results further indicated that KPNA4 may involve in FAK signaling in PDAC. Recent studies have demonstrated that FAK can mediate downstream of αVβ3 integrin to positively regulate the expression of PD-L1 in tumor cells (49). Thus, we wondered whether the expression of KPNA4 was related to PD-L1. Remarkably, analysis indicated that KPNA4 had a significant and positive correlation with CD274 (encoding PD-L1) (Figure 7E), and the relationship was further verified in GSE15471 and GSE16515 datasets (Figure 7F and Supplementary Figure 4D). To experimentally validate these findings, we knocked down KPNA4 by small interfering RNA (siKPNA4) in MIA PaCa-2 and PANC-1 pancreatic cancer cell lines with high KPNA4 expression (Figures 7G, H). Consistently, the expression levels of FAK, PIK3CA and CD274 were significantly downregulated after
KPNA4 knockdown, whereas AKT1 expression had nothing to do with KPNA4. Overall, our results suggested that KPNA4 may promote FAK signaling and PD-L1 expression in PDAC cells, which could be responsible for the KPNA4-dependent malignant behaviors of cancer cells and immunosuppressive TME in PDAC patients.

**DISCUSSION**

PDAC is one of the most lethal malignancies and is often diagnosed at an advanced stage with high mortality rates (50). Therefore, it is necessary to find accurate biomarkers for the early detection and prognostic prediction of PDAC. Recent studies have reported several potential biomarkers for PDAC. For example, COL11A1 was considered to be a prognostic marker of PDAC and was significantly related to tumor immune infiltration (51). Additionally, S100A16 was discovered as an important biomarker for the diagnosis and prognosis of PDAC (52).

Studies have shown that the KPNA family as nuclear transport factors can mediate the translocation of several transcription factors to the nucleus, and is closely associated with a variety of cancers including PDAC (53). For instance, high expressions of KPNA2 and KPNA7 have been found to be significantly correlated with poor prognosis in PDAC (54, 55). In the present study, we focused on KPNA4, which is a member of the KPNA family (11). According to a recent study, high-expressed KPNA4 in hepatocellular carcinoma (HCC) can indicate poor survival outcome, supporting KPNA4 as an independent predictor of HCC prognosis (16). However, the prognostic value of KPNA4 in other cancers has yet to be reported. To this end, we first analyzed the expression of KPNA4 in PDAC via bioinformatics methods. The results showed that the mRNA and protein levels of KPNA4 were significantly increased in PDAC compared with that in normal pancreas tissues, which was further verified in cell lines and our own clinical samples. Further clinical correlation analysis demonstrated that patients with advanced stage and high histological grade tended to express higher level of KPNA4, and KPNA4 expression was also associated with tumor infiltration and lymph node metastasis. Moreover, patients with high-expressed KPNA4 had a tendency to show poorer response to therapy. These results were highly consistent with the survival significance of KPNA4 in PDAC. Stratified survival analysis and Cox regression analysis further revealed that high KPNA4 expression could independently predict unfavorable
prognosis. Thus, all these results above suggest that KPNA4 can act as a potential prognostic biomarker for PDAC patients.

It has been reported that only a minority of pancreatic cancers are immunologically active, and immune cells in the TME, especially immunosuppressive cells, are thought to play a vital role in this process (6, 9). Previous research revealed a positive relationship between KPNA4 and immune cell infiltration in HCC, suggesting that KPNA4 may participate in regulating TME (16). However, whether KPNA4 relates to immune infiltration in other cancers has not been elucidated yet. In our work, immune infiltration analysis demonstrated that KPNA4 expression was significantly and positively correlated with the infiltration of macrophage, neutrophil, DCs, Tregs and CAFs in PDAC TME. Tumor-associated macrophages suppress the function of nature killer cells and T cells by expressing non-classical MHC class I molecules and ligands of immune checkpoint receptors, thereby promoting tumor growth and invasion (6). High levels of intratumoral neutrophil infiltration are considered to be significantly correlated with poor prognosis of multiple cancers (37). The infiltration of intratumoral Tregs increases with the progression of PDAC, and also has significant relationship with unfavorable survival outcome (36). Moreover, CAFs, which are the main producers of extracellular matrix proteins, are considered to be implicated in many tumor-promoting processes (38). Therefore, KPNA4 may mediate the infiltration of these immunosuppressive immune cells, thereby promoting cancer progression. Moreover, our study revealed that high KPNA4 expression was significantly positively correlated with the infiltration of CD8+ T cells, which have potential tumoricidal activity. Nevertheless, there was no relationship between the expression of KPNA4 and cytotoxic CD8+ T cells markers (GZMA, GZMB and IFNG). Further analysis revealed the correlation between KPNA4 and TIM3 (encoded by HAVCR2), which is a marker of exhausted T cells and has been reported to be tightly associated with poor survival outcome in PDAC (40). These results collectively demonstrate that although KPNA4 is potentially related to CD8+ T cells infiltration in PDAC, it may shape an immunosuppressive TME and promote T cell exhaustion, thus inhibiting cytotoxic T cells and anti-tumor response.

The indirect interaction between FAK and integrin at focal adhesion canonically mediates FAK signaling, which has been proven to regulate motility, invasion and survival of cancer cells, thereby promoting cancer growth and metastasis (17). Overexpression of FAK is regarded as a key feature of PDAC and many studies have demonstrated the anti-tumor effect of FAK inhibitors on human pancreatic cancer cells (44, 56). Intriguingly, functional enrichment analysis and PPI network in our study illustrate that KPNA4 co-expressed genes in PDAC are mainly involved in focal adhesion and PI3K-Akt pathways, which has been reported to be the downstream pathway of FAK signaling in PDAC (57). Correlation analysis also revealed that KPNA4, FAK, PIK3CA, and AKT1 showed a highly positive correlation with each other. Moreover, in vitro experiment further indicated that KPNA4 knockdown had a negative regulatory effect on the expression of FAK and PIK3CA. Consistently, our loss-of-function experiments revealed that KPNA4 silencing suppressed proliferation and migration of PDAC cells, confirming its tumor-supporting roles in pancreatic cancer. Hereby we postulate that KPNA4 may play a tumor-promoting role via FAK signaling. Further studies are necessary to unravel the underlying mechanisms.

Increasing evidence has shown that FAK can exert immunomodulatory roles in cancers. FAK signaling create the immunosuppressive TME by regulating the expression of...
chemokines such as CXCL12 and CCL5, enabling tumors to escape anti-tumor immunity (58). More importantly, FAK was found to function downstream of αVβ3 integrin to positively regulate the interferon signaling, and then promote the nuclear translocation of transcription factor STAT1/2, thereby activating PD-L1 expression and promoting tumor immune escape (49). Our study illustrated that KPNA4 was positively related to PD-L1 expression in multiple PDAC cohorts, and KPNA4 silencing significantly decreased PD-L1 expression in PDAC cell lines. Notably, studies have elucidated that KPNA family can mediate the nuclear transport of a variety of transcription factors including STAT1/2 (59). Although our results showed that KPNA4 knockdown suppressed FAK expression in vitro, these previous researches lead to our assumption that KPNA4 may also act downstream of FAK signaling and affect the expression of PD-L1. Furthermore, although PDAC is regarded as an immunologically cold tumor type, studies have revealed that patients with PD-L1/CD8-high subtype are still associated with immunologically cold tumor type. Studies have revealed that KPNA4 exerts tumor-promoting roles in PDAC cells and is expected to reverse the tumor-promoting microenvironment and enhance anti-tumor immunity.

Still, our study has some limitations. Majority of the data used in our work came from online databases, thus a large-scale study is needed for further validation. Additionally, proliferation and migration promoting functions of KPNA4 in vitro require to be verified by in vivo xenograft tumor model and metastasis model. Further in vitro and in vivo experiments are needed to explore the specific mechanism of KPNA4 in PDAC and its immunosuppressive TME.

CONCLUSIONS

In conclusion, our study explored the expression and prognostic value of KPNA4 in PDAC patients, revealing that KPNA4 can be used as an independent prognostic biomarker for PDAC. KPNA4 exerts tumor-promoting roles in PDAC cells and is associated with the immunosuppressive TME, which may be partly mediated by FAK signaling and PD-L1 expression. On this basis, further experimental researches are needed to uncover the exact mechanisms, so as to provide a new therapeutic target for therapy of pancreatic cancer.

REFERENCES

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res (2014) 74(11):2913–21. doi: 10.1158/0008-5472.CAN-14-0155
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistic. CA Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654
3. Sun D, Cao M, Li H, He S, Chen W. Cancer Burden and Trends in China: A Review and Comparison With Japan and South Korea. Chin J Cancer Res (2020) 32(2):129–39. doi: 10.21147/j.issn.1000-9604.2020.02.01
4. Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers (Basel) (2018) 10(1):24. doi: 10.3390/cancers10010024

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Shanghai General Hospital, Shanghai Jiaotong University School of Medicine. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

J-PB and C-LX contributed equally to design the study, obtain the data, and write the manuscript. G-YH reviewed the manuscript and supervised the study. BL, Z-KW, and JS collected the clinical samples and analyzed the results. P-LS and QP assisted in statistical analysis. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.834728/full#supplementary-material

ACKNOWLEDGMENTS

We would like to acknowledge the reviewers for their precious comments on our study.

FUNDING

This study was sponsored by National Natural Science Foundation of China (81970556 and 82170652).

AUTHOR CONTRIBUTIONS

J-PB and C-LX contributed equally to design the study, obtain the data, and write the manuscript. G-YH reviewed the manuscript and supervised the study. BL, Z-KW, and JS collected the clinical samples and analyzed the results. P-LS and QP assisted in statistical analysis. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.834728/full#supplementary-material

REFERENCES

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res (2014) 74(11):2913–21. doi: 10.1158/0008-5472.CAN-14-0155
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistic. CA Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654
3. Sun D, Cao M, Li H, He S, Chen W. Cancer Burden and Trends in China: A Review and Comparison With Japan and South Korea. Chin J Cancer Res (2020) 32(2):129–39. doi: 10.21147/j.issn.1000-9604.2020.02.01
4. Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers (Basel) (2018) 10(1):24. doi: 10.3390/cancers10010024
5. National Health Commission Of The People’s Republic Of China. Chinese Guidelines for Diagnosis and Treatment of Pancreatic Cancer 2018 (English Version). Chin J Cancer Res (2019) 31(2):278–94. doi: 10.21147/j.issn.1000-9604.2019.02.03
6. Ho WJ, Jaffee EM, Zheng L. The Tumour Microenvironment in Pancreatic Cancer – Clinical Challenges and Opportunities. Nat Rev Clin Oncol (2020) 17(9):527–40. doi: 10.1038/s41571-020-0363-5
7. Whatcott CJ, Diep GH, Jiang P, Watanabe A, Lobello J, Sima C, et al. Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. Clin Cancer Res (2015) 21(15):3561–8. doi: 10.1158/1078-0432.CCR-14-1051
8. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Higgorani SR. Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma. Cancer Cell (2012) 21(3):418–29. doi: 10.1016/j.ccr.2012.01.007
9. Bailey P, Chang DK, Nomes K, Johns AL, Patch AM, Gingras MC, et al. Genomic Analyses Identify Molecular Subtypes of Pancreatic Cancer. *Nature* (2018) 55(1):79((2)):52–52. doi: 10.1038/nature25365

10. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and Activity of Anti-PD-L1 Antibody in Patients With Advanced Cancer. *N Engl J Med* (2012) 366(26):2455–65. doi: 10.1056/NEJMoa120694

11. Herold A, Traunt R, Wiegand H, Cullen BR. Determination of the Functional Domain Organization of the Importin Alpha Nuclear Import Factor. *J Biol* (1998) 143(2):309–18. doi: 10.1083/jcb.143.2.309

12. Wang H, Tao Y, Yan W, Feng Y, Wang Y, Cai J, et al. Upregulation of miR-181a Reverses Mesenchymal Transition by Targeting KPNA4 in Glioblastoma. *Sci Rep* (2015) 5:13072. doi: 10.1038/srep13072

13. Yang J, Lu C, Wei J, Guo Y, Liu W, Luo L, et al. Inhibition of KPNA4 Attenuates Prostate Cancer Metastasis. *Oncogene* (2017) 36(20):2688–70. doi: 10.1038/onc.2016.440

14. Li X, Yu M, Yang C. YY1-Mediated Overexpression of Long Noncoding RNA MCM3AP-AS1 Accelerates Angiogenesis and Progression in Lung Cancer by Targeting miR-340-5p/KPNA4 Axis. *J Cell Biochem* (2020) 121(3):2258–67. doi: 10.1002/jcb.29448

15. Wang D, Cui Y, Wang A, Zhao L, Li P. MiR-596 Activated by EP300 Controls the Expression and Hybridization Array Data Repository. Nucleic Acids Res (2017) 45(D1):D956. doi: 10.1093/nar/gkw1090

16. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. *Nucleic Acids Res* (2017) 45(W1):W98–W102. doi: 10.1093/nar/gkw247

17. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI Gene Expression and Hybridization Array Data Repository. *Nucleic Acids Res* (2002) 30(1):207–10. doi: 10.1093/nar/30.1.207

18. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: Archive for Functional Genomics Data Sets—Update. *Nucleic Acids Res* (2013) 41(Database issue):d991–995. doi: 10.1093/nar/gkt1193

19. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-Based Map of the Human Proteome. *Science* (2015) 347(6200):1260419. doi: 10.1126/science.1260419

20. Buchholz M, Braun M, Heinemann A, Kessler HA, Klöppel G, Schmieg W, et al. Transcriptome Analysis of Microdissected Pancreatic Intraepithelial Neoplastic Lesions. *Oncogene* (2005) 24(44):6626–36. doi: 10.1038/sj.onc.1208804

21. Ishikawa M, Yoshida K, Yamashita Y, Ota T, Kakuda S, Kanohi K, et al. Experimental Trial for Diagnosis of Pancreatic Ductal Carcinoma Based on Gene Expression Profiles of Pancreatic Ductal Cells. *Cancer Sci* (2005) 96(7):387–93. doi: 10.1111/j.1349-7006.2005.00064.x

22. Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): An Immeasurable Source of Knowledge. *Nat Protoc* (2009) 4(1):44–52. doi: 10.1038/nprot.2008.211

23. Hiraoka N, Onozato K, Kosuge T, Hirohashi S, Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Carcinoma and its Premalignant Lesions. *Clin Cancer Res* (2006) 12(18):5423–34. doi: 10.1158/1078-0432.CCR-06-0369

24. Shen M, Hu P, Donskov F, Wang G, Liu Q, Du J. Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis. *PloS One* (2014) 9(6):e98259. doi: 10.1371/journal.pone.0098259

25. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined Gene Expression Analysis of Whole-Tissue and Microdissected Pancreatic Ductal Adenocarcinoma Identifies Genes Specifically Overexpressed in Tumor Epithelia. *Hepatogastroenterology* (2008) 55(88):2016–2016.

26. Bao et al. KPNA4 in Pancreatic Ductal Adenocarcinoma  |  Frontiers in Oncology | www.frontiersin.org  |  March 2022 |  Volume 12 |  Article 834728
Hepatic Stellate Cell Proliferation and Type I Collagen Expression. *J Biol Chem* (2003) 278(10):8083–90. doi: 10.1074/jbc.M212927200

49. Vannini A, Leoni V, Barboni C, Sanapo M, Zaghini A, Malatesta P, et al. Alphavbeta3-Integrin Regulates PD-L1 Expression and is Involved in Cancer Immune Evasion. *Proc Natl Acad Sci U S A* (2019) 116(40):20141–50. doi: 10.1073/pnas.1901931116

50. Klein AP. Pancreatic Cancer Epidemiology: Understanding the Role of Lifestyle and Inherited Risk Factors. *Nat Rev Gastroenterol Hepatol* (2021) 18(7):493–502. doi: 10.1038/s41575-021-00457-x

51. Zheng X, Liu X, Zheng H, Wang H, Hong D. Integrated Bioinformatics Analysis Identified COL11A1 as an Immune Infiltrates Correlated Prognosticator in Pancreatic Adenocarcinoma. *Int Immunopharmacol* (2021) 90:106982. doi: 10.1016/j.intimp.2020.106982

52. Tu G, Gao W, Li Y, Dian Y, Xue B, Niu L, et al. Expression and Prognostic Value of S100A16 in Pancreatic Cancer Via Integrated Bioinformatics Analyses. *Front Cell Dev Biol* (2021) 9:645641. doi: 10.3389/fcell.2021.645641

53. Cagatay T, Choock YM. Karyopherins in Cancer. *Curr Opin Cell Biol* (2018) 52:30–42. doi: 10.1016/j.ceb.2018.01.006

54. Vuorinen EM, Rajala NK, Ihalainen TO, Kallioniemi A. Depletion of Nuclear Import Protein Karyopherin Alpha 7 (KPNA7) Induces Mitotic Defects and Deformation of Nuclei in Cancer Cells. *BMC Cancer* (2018) 18(1):325. doi: 10.1186/s12885-018-4261-5

55. Zhou K-X, Huang S, Hu L-P, Zhang X-L, Qin W-T, Zhang Y-L, et al. Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC. *J Immunol Res* (2021) 2021:1–13. doi: 10.1155/2021/6694392

56. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, et al. A Novel Small Molecule Inhibitor of FAK Decreases Growth of Human Pancreatic Cancer. *Cell Cycle* (2009) 8(15):2435–43. doi: 10.4161/cc.8.15.9145

57. Liu H, Tao H, Wang H, Yang Y, Yang R, Dai X, et al. Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer. *Front Oncol* (2020) 10:619317. doi: 10.3389/fonc.2020.619317

58. Symeonides SN, Anderton SM, Serrels A. FAK-Inhibition Opens the Door to Checkpoint Immunotherapy in Pancreatic Cancer. *J Immunother Cancer* (2017) 5:17. doi: 10.1186/s40428-017-0217-6

59. Melen K, Fagerlund R, Franke J, Kohler M, Kinnunen I. Importin Alpha Nuclear Localization Signal Binding Sites for STAT1, STAT2, and Influenza A Virus Nucleoprotein. *J Biol Chem* (2003) 278(30):28193–200. doi: 10.1074/jbc.M303571200

60. Danilova L, Ho WJ, Zhu Q, Vitthayathil T, De Jesus-Acosta A, Azad NS, et al. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas With Favorable Survival. *Cancer Immunol Res* (2019) 7(6):886–95. doi: 10.1158/2326-6066.CIR-18-0822

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Bao, Xu, Li, Wu, Shen, Song, Peng and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.